
Published On: Feb 2022
Published On: Feb 2022
According to a new market research study on “Asia Pacific Hemostasis Analyzers Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Test, End User and Country” is expected to reach US$ 1,424.59 million by 2028 from US$ 736.69 million in 2021. The market is estimated to grow at a CAGR of 9.9% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific hemostasis analyzers market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to rising number of cardiovascular diseases and rise in the geriatric population are the key factors driving the market growth. However, the market is expected to experience slow growth during the forecast period owing to high cost of fully automated hemostasis analyzer.
The socio-economics were severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Recently, patients with both hypertension and obesity have been increasing in Japan. These patients are at exceptionally high risk for severe disease in COVID-19 and thus need careful observation and intensive treatment. Comparable to hypertension, the definition of obesity is not constant among studies/countries, which requires consideration. However, it is essential to note that the therapeutic mechanism of CCB against COVID-19 still awaits further investigation and randomized controlled clinical trials. The pandemic has affected three main aspects of the global economy: production, supply chain, and firms and financial markets. Japan, China, South Korea, India, and Australia are the most affected countries due to the increasing number of COVID-19 cases and the associated deaths. This scenario positively impacts the hemostasis analyzers. This pandemic is affecting the business operation of the various key players operating in this region.
The market for Asia Pacific Hemostasis Analyzers Market is segmented into the product type, test, end user and country. Based on product type, the Asia Pacific Hemostasis Analyzers Market is segmented into laboratory analyzer, and point-of-care testing systems, whereas laboratory analyzer sub segmented into automated systems, semi-automated systems, and manual systems. In 2021, the laboratory analyzer segment accounted for the largest market share. The growth of these segments is attributed to an increase in the prevalence of chronic illnesses like blood disorders and cardiovascular diseases, development of point of care (POC) coagulation testing, and the surge in laboratory automation is likely to create opportunity in the forecast year. However the point-of-care testing systems segment is estimated to register the highest CAGR during the forecast period.
Siemens Healthineers AG, Abbott, Sysmex Corporation, Nihon Kohden Corporation, THERMO FISHER SCIENTIFIC INC., HOFFMANN-LA ROCHE LTD., Instrumentation Laboratory Company. Among the leading companies in the Asia Pacific Hemostasis Analyzers Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for Asia Pacific hemostasis analyzers market is segmented into product type, test, and end user. Based on product type, the Asia Pacific hemostasis analyzers market is segmented into laboratory analyzer [automated systems, semi-automated systems, and manual systems], and point-of-care testing systems. Based on test, the Asia Pacific hemostasis analyzers market is segmented into activated partial thromboplastin time, d-dimer test, fibrinogen test, prothrombin time (PT) test, and others. Based on end user, the Asia Pacific hemostasis analyzers market is segmented into hospitals/ clinics, independent diagnostic laboratories, home care setting, and others. By Geographically, Asia Pacific hemostasis analyzers market is segmented into (China, Japan, India, Australia, South Korea, and Rest of APAC).
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com